ArticleCell reports2014
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell state.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 142 citations in OpenAlex.
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- ZFHX4 is necessary for dopaminergic neuron differentiation and controls cell cycle by regulating LIN28A.Stem cell reports · 2026Article
- Mapping of the hSOX10 Proximal Protein Interactome in Human Melanoma.Journal of proteome research · 2026Article
- The NuRD chromatin remodeling complex contributes to repairing exogenous double-strand breaks in the Caenorhabditis elegans germline.Genetics · 2026Article
- Genetic analysis of Han-Chinese patients with isolated congenital ptosis.International journal of ophthalmology · 2026Article
- NuRD chromatin remodeling is required to repair exogenous DSBs in thebioRxiv : the preprint server for biology · 2025Article
- Mapping of the hSOX10 protein interactome in human melanoma.bioRxiv : the preprint server for biology · 2025Article
- Loss of function of the zinc finger homeobox 4 gene, ZFHX4, underlies a neurodevelopmental disorder.American journal of human genetics · 2025Article
- Role of ZFHX4 in orofacial clefting based on human genetic data and zebrafish models.European journal of human genetics : EJHG · 2025Article
- LncRNA ZFHX4-AS1 initiates an oncogenic axis involving a ZFHX4/SOX2 positive feedback loop to accelerate glioma progression.Frontiers in oncology · 2025Article
- Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.Investigational new drugs · 2024Article
- How does CHD4 slide nucleosomes?Biochemical Society transactions · 2024Review
- Identification of Rocaglate Acyl Sulfamides as Selective Inhibitors of Glioblastoma Stem Cells.ACS central science · 2024Article
- Loss-of-function of the Zinc Finger Homeobox 4 (medRxiv : the preprint server for health sciences · 2024Article
- A hypoxia-glycolysis-lactate-related gene signature for prognosis prediction in hepatocellular carcinoma.BMC medical genomics · 2024Article
- CHD4 acts as a prognostic factor and drives radioresistance in HPV negative HNSCC.Scientific reports · 2024Article
- Identification of fatty acid oxidation-related subtypes by integrated analysis of bulk- and single-cell transcriptome profiling in colorectal cancer.Journal of gastrointestinal oncology · 2024Article
- Integration of single-cell regulon atlas and multi-omics data for prognostic stratification and personalized treatment prediction in human lung adenocarcinoma.Journal of translational medicine · 2023Article
- Epigenetic regulation of plastin 3 expression by the macrosatellite DXZ4 and the transcriptional regulator CHD4.American journal of human genetics · 2023Article
- The epigenetic factor CHD4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer.Journal of translational medicine · 2023Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 15 institutions in 3 countries.
Yakov ChudnovskyWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Dohoon KimWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Siyuan ZhengDepartment of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX 77030, USA.
Warren A WhyteWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Mukesh BansalDepartment of Systems Biology, Columbia University, New York, NY 10032, USA; Center for Computational Biology and Bioinformatics, Columbia University, New York, NY 10032, USA.
Mark-Anthony BrayBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Shuba GopalBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Matthew A TheisenDepartment of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Steve BilodeauCentre de Recherche sur le Cancer and Centre de Recherche du CHU de Québec (Hôtel-Dieu de Québec), Université Laval, QC G1R 2J6, Canada; Département de Biologie Moléculaire, Biochimie Médicale et Pathologie, Faculté de Médecine, Université Laval, QC G1R 2J6, Canada.
Prathapan ThiruWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Julien MuffatWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Omer H YilmazWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02139, USA.
Maya MitalipovaWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA.
Kevin WoolardDepartment of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA 95616, USA.
Jeongwu LeeDepartment of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland, OH 44195, USA.
Riko NishimuraDepartment of Molecular and Cellular Biochemistry, Osaka University Graduate School of Dentistry, Suita, Osaka 565-0871, Japan.
Nobuo SakataDepartment of Biochemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan.
Howard A FineDivision of Hematology and Medical Oncology, New York University Cancer Institute, New York University Langone Medical Center, New York, NY 10016, USA; Brain Tumor Center, New York University Cancer Institute, New York University Langone Medical Center, New York, NY 10016, USA.
Anne E CarpenterBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Serena J SilverBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Roel G W VerhaakDepartment of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA.
Andrea CalifanoDepartment of Systems Biology, Columbia University, New York, NY 10032, USA; Center for Computational Biology and Bioinformatics, Columbia University, New York, NY 10032, USA; Department of Biomedical Informatics, Columbia University, New York, NY 10032, USA; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA; Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.
Richard A YoungWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Keith L LigonDepartment of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
Ingo K MellinghoffDepartment of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Department of Pharmacology, Weill-Cornell Graduate School of Biomedical Sciences, New York, NY 10021, USA.
David E RootBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
David M SabatiniWhitehead Institute for Biomedical Research, Cambridge, MA 02142, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; The David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Cambridge, MA 02139, USA. Electronic address: sabatini@wi.mit.edu.
William C HahnBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: william_hahn@dfci.harvard.edu.
Milan G ChhedaBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Broad Institute · USWhitehead Institute for Biomedical Research · USBrigham and Women's Hospital · USThe University of Texas MD Anderson Cancer Center · USCancer Genetics (United States) · USCleveland Clinic Lerner College of Medicine · USColumbia University · USDana-Farber Cancer Institute · USHôtel-Dieu de Québec · CAKoch Institute for Integrative Cancer Research At MITMemorial Sloan Kettering Cancer Center · USNYU Langone Health · USOsaka University · JPShowa Pharmaceutical University · JPUniversity of California, Davis · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MNation Center: Multi-Scale Study- Cellular Networks(RMI)U54CA121852 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2005 to 2015
$37.4MTransgenic Mouse and Biobank CoreP01CA095616 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2003 to 2012
$20.3MTranscriptional Regulatory Networks in Living CellsR01HG002668 · NHGRI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI YOUNG, RICHARD · 2003 to 2016
$17.9MTraining Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3MIntegrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)U24CA143883 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AKBANI, REHAN, MILLS, GORDON B. · 2009 to 2016
$10.6MTherapeutic Opportunities for Pediatric AstrocytomaP01CA142536 · NCI · DANA-FARBER CANCER INST · PI STILES, CHARLES D · 2011 to 2015
$7.9MThe Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8MRegulation of the mTOR Pathway By NutrientsR01CA103866 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEISSMAN, JONATHAN S. · 2004 to 2021
$7.0MSystems Biology of Tumor Progression and Drug ResistanceU01CA168426 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2016
$6.5MCell Growth Signaling in Cancer DevelopmentR01CA129105 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEISSMAN, JONATHAN S. · 2008 to 2021
$5.9MContinued Development of CellProfiler Cell Image Analysis SoftwareR01GM089652 · NIGMS · BROAD INSTITUTE, INC. · PI CARPENTER, ANNE E. · 2010 to 2016
$3.7MHoward Hughes Medical InstituteNCI NIH HHS K12 CA090354NCI NIH HHS K12CA090354NCI NIH HHS P01 CA095616NCI NIH HHS P01CA095616NCI NIH HHS P01 CA142536NCI NIH HHS P01CA142536NCI NIH HHS P30 CA016672NCI NIH HHS P30CA016672NCI NIH HHS R01 CA103866NCI NIH HHS R01 CA129105NCI NIH HHS R01CA129105NCI NIH HHS R01CA146455NCI NIH HHS R01 CA170592NCI NIH HHS R01CA170592NCI NIH HHS U01 CA168426NCI NIH HHS U01CA168426NCI NIH HHS U01 CA176058NCI NIH HHS U01CA176058NCI NIH HHS U24 CA143883NCI NIH HHS U24CA143883NCI NIH HHS U54 CA121852NCI NIH HHS U54CA121852NHGRI NIH HHS R01 HG002668NHGRI NIH HHS R01HG002668NIA NIH HHS K99 AG045144NIGMS NIH HHS R01 GM089652NIGMS NIH HHS R01GM089652NINDS NIH HHS K08 NS062907NINDS NIH HHS K08NS062907NINDS NIH HHS R01 NS080944NINDS NIH HHS R01NS080944
Abstract
Glioblastoma (GBM) harbors subpopulations of therapy-resistant tumor-initiating cells (TICs) that are self-renewing and multipotent. To understand the regulation of the TIC state, we performed an image-based screen for genes regulating GBM TIC maintenance and identified ZFHX4, a 397 kDa transcription factor. ZFHX4 is required to maintain TIC-associated and normal human neural precursor cell phenotypes in vitro, suggesting that ZFHX4 regulates differentiation, and its suppression increases glioma-free survival in intracranial xenografts. ZFHX4 interacts with CHD4, a core member of the nucleosome remodeling and deacetylase (NuRD) complex. ZFHX4 and CHD4 bind to overlapping sets of genomic loci and control similar gene expression programs. Using expression data derived from GBM patients, we found that ZFHX4 significantly affects CHD4-mediated gene expression perturbations, which defines ZFHX4 as a master regulator of CHD4. These observations define ZFHX4 as a regulatory factor that links the chromatin-remodeling NuRD complex and the GBM TIC state.
Indexed as
Gene Expression Regulation, NeoplasticAnimalsAutoantigensCarcinogenesisCell Line, TumorGlioblastomaHomeodomain ProteinsHumansMi-2 Nucleosome Remodeling and Deacetylase ComplexMice, Inbred NODProtein BindingTranscription FactorsTranscription, GeneticAutoantigensCHD4 protein, humanHomeodomain ProteinsMi-2 Nucleosome Remodeling and Deacetylase ComplexTranscription FactorsZFHX4 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.